All In Biotech

Drug Trial Radar · NCT03025308

Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

A Multicenter, Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects With Rheumatoid Arthritis

Last checked: Nov 19, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,731 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,731

Actual

Start

Feb 28, 2017

Primary completion

May 16, 2025

Study completion May 16, 2025

Sponsor

Lead sponsor
Alfasigma S.p.A.Industry
Sponsor type
Industry
Collaborators
Gilead Sciences
First posted
Jan 19, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the long-term safety and tolerability of filgotinib in participants who have completed one of the parent studies of filgotinib in rheumatoid arthritis (RA).

Conditions

  • Rheumatoid Arthritis

Interventions

  • FilgotinibDrug

    Tablet(s) administered orally once daily

  • Placebo to match filgotinibDrug

    Tablet(s) administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Reported Treatment-Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)Time frame: Day 1 to Week 376 (end of study)
  2. Number of Participants Who Reported Treatment-Emergent Graded Laboratory Abnormalities in Serum Chemistry ParametersTime frame: Day 1 to Week 376 (end of study)
  3. Number of Participants Who Reported Treatment-Emergent Graded Laboratory Abnormalities in Hematology ParametersTime frame: Day 1 to Week 376 (end of study)
  4. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)Time frame: Baseline and At Week 312
  5. Change From Baseline in Pulse RateTime frame: Baseline and At Week 312
  6. Change From Baseline in Respiration RateTime frame: Baseline and At Week 312

Locations

345 sites in 32 countries. Site status is shown where the registry gives one.

  • Rheumatology Associates of North Alabama, PC

    Huntsville, Alabama

  • Arthrocare, Arthritis Care & Research PC

    Gilbert, Arizona

  • Arizona Arthritis & Rheumatology Associates, P.C.

    Phoenix, Arizona

  • Arizona Arthritis & Rheumatology Associates, P.C.

    Tucson, Arizona

  • Medvin Clinical Research

    Covina, California

  • C.V. Mehta M.D. Medical Corporation

    Hemet, California

  • University of California San Diego (UCSD) - Perlman Ambulatory Clinic

    La Jolla, California

  • Keck Medicine of USC- Division of Rheumatology

    Los Angeles, California

  • Desert Medical Advances

    Palm Desert, California

  • Stanford University Hospitals and Clinics (Immunology & Rheumatology)

    Palo Alto, California

  • C.V. Mehta Medical Corporation

    Riverside, California

  • Inland Rheumatology Clinical Trials, Inc.

    Upland, California

  • Desert Valley Medical Group

    Victorville, California

  • Medvin Clinical Research

    Whittier, California

  • AARDS Research, Inc.

    Aventura, Florida

  • Clinical Research of West Florida, Inc.

    Clearwater, Florida

  • Omega Research Consultants, LLC

    DeBary, Florida

  • University of Florida College of Medicine, Jacksonville - Rheumatology Research

    Jacksonville, Florida

  • Suncoast Research Group, LLC

    Miami, Florida

  • San Marcus Research Clinic, Inc.

    Miami Lakes, Florida

  • Suncoast Clinical Research, Inc.

    New Port Richey, Florida

  • Omega Research Consultants LLC

    Orlando, Florida

  • IRIS Research and Development, LLC

    Plantation, Florida

  • Jefrey D. Lieberman, MD, P.C.

    Decatur, Georgia

  • Springfield Clinic

    Springfield, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Heartland Research Associates, LLC

    Wichita, Kansas

  • Center For Arthritis and Osteoporosis

    Elizabethtown, Kentucky

  • Bluegrass Community Research, Inc.

    Lexington, Kentucky

  • Klein & Associates, M.D., P.A.

    Cumberland, Maryland

  • Arthritis Treatment Center

    Frederick, Maryland

  • Klein & Associates, M.D., P.A.

    Hagerstown, Maryland

  • The Center For Rheumatology And Bone Research

    Wheaton, Maryland

  • Clinical Pharmacology Study Group

    Worcester, Massachusetts

  • Umass Memorial Medical Center- Memorial Campus

    Worcester, Massachusetts

  • Henry Ford Health System

    Detroit, Michigan

  • Shores Rheumatology, PC

    Saint Clair Shores, Michigan

  • St. Paul Rheumatology, PA

    Eagan, Minnesota

  • Arthritis Associates, PLLC

    Hattiesburg, Mississippi

  • North Mississippi Medical Clinics, Inc.

    Tupelo, Mississippi

Showing 40 of 345 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.